AI-based cancer imaging diagnostics have improved enormously over the last few years, with some programs already in use in the clinic, but researchers advise caution with more widespread rollout until more large-scale testing is completed.
The USC researchers found that bilateral temporal/parietal and left frontal lobes are susceptible to lung cancer, right frontal and occipital lobes to melanoma, cerebellum to breast cancer, and brainstem to renal cell carcinoma.
SUMOylation is a biochemical process that peppers proteins with small ubiquitin-like modifiers (SUMOs). Earlier studies have shown SUMOylation suppresses type I interferon (IFN1) signaling that helps mobilize innate and acquired immune response against cancer.
Immunocore's tebentafusp is the first T-cell receptor and the first systemic therapy that shows a significant survival benefit for patients with metastatic uveal melanoma, according to results from a Phase III trial.
A new immunotherapy using modified cells targeting two different antigens was highly effective in a mouse model of human neuroblastoma, according to a study led by researchers from the UNC Lineberger Comprehensive Cancer Center and the UNC School of Medicine.
Peptidylarginine deiminase 4 (PADI4) and hypoxia-inducible factor 1 (HIF-1) ramp up their activity under low-oxygen conditions that are typically found in a fast-growing tumor, to allow the formation of new blood vessels that feed the cancer’s growth.
A clinical study evaluated by the FDA found that Paige Prostate improved detection of cancer on individual slide images by 7.3% on average when compared to pathologists’ unassisted reads for whole slide images of individual biopsies, with no impact on the read of benign slide images.
A new genomics program in South Carolina will enroll 100,000 volunteers over 4 years who will undergo exome testing to provide useful health information to the patients and their clinicians from the start, while also contributing to medical research.
The nanobodies, which bind tightly to the SARS-CoV-2 virus, neutralizing it in cell culture, could provide a cheaper and easier to use alternative to human antibodies taken from patients who have recovered from COVID-19.
The survival of women with brain metastases from breast cancer remains very poor, with over 80% dying within a year of their diagnosis. The researchers identified the protein IL13Ra2 as a target, with its known vulnerability to CAR T-cell treatment in clinical trials on brain tumors.